Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1

Erzsébet Lizanecz, Zsolt Bagi, Eniko T. Pásztor, Zoltán Papp, István Édes, Noémi Kedei, Peter M. Blumberg, Attila Tóth

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

It has been proposed that activation of vanilloid receptor-1 (TRPV1) affects the vasotone of resistance arteries. One of the endogenous activators of TRPV1 is anandamide. The effects of anandamide on TRPV1 responsiveness were tested on isolated, pressurized (80 mm Hg) skeletal muscle (m. gracilis) arterioles (179 ± 33 μm in diameter). We found that the TRPV1 agonist capsaicin (1 μM) elicited a substantial constriction in isolated arterioles (51 ± 12%). In contrast, anandamide (0-100 μM) did not affect arteriolar diameter significantly (3 ± 5%). Isolated vessels were also preincubated with anandamide (30 μM for 20 min). This anandamide pretreatment completely blocked capsaicin-induced arteriolar constriction (response decreased to 1 ± 0.6%), and this inhibition was reversed by a protein phosphatase-2B inhibitor (cyclosporin-A; 100 nM, 5 min) treatment (constriction, 31 ± 1%). An exogenous TRPV1-expressing cell line [Chinese hamster ovary (CHO)-TRPV1] was used to specifically evaluate TRPV1-mediated effects of anandamide. The efficacy of anandamide in this system, as determined by 45Ca2+ uptake, was 65 ± 8% of that of capsaicin. Upon treatment of the cells with cyclosporin-A or the protein kinase C activator phorbol 12-myristate 13-acetate (PMA), anandamide was transformed to a full agonist. Anandamide treatment caused an acute desensitization in these cells as measured by intracellular Ca2+ imaging. Application of cyclosporin-A or PMA reversed this desensitization. Our data suggest that anandamide may cause a complete (albeit phosphorylation-dependent) desensitization of TRPV1 in skeletal muscle arterioles and in CHO-TRPV1 cells, which apparently transforms the ligand-gated TRPV1 into a phosphorylation-gated channel. This property of anandamide may provide a new therapeutic strategy to manipulate TRPV1 activity.

Original languageEnglish (US)
Pages (from-to)1015-1023
Number of pages9
JournalMolecular Pharmacology
Volume69
Issue number3
DOIs
StatePublished - Mar 1 2006

Fingerprint

Arterioles
Cricetulus
Ovary
Skeletal Muscle
Phosphorylation
Capsaicin
Constriction
Cyclosporine
Acetates
anandamide
vanilloid receptor subtype 1
Protein Kinase C
Arteries
Ligands
Cell Line

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1. / Lizanecz, Erzsébet; Bagi, Zsolt; Pásztor, Eniko T.; Papp, Zoltán; Édes, István; Kedei, Noémi; Blumberg, Peter M.; Tóth, Attila.

In: Molecular Pharmacology, Vol. 69, No. 3, 01.03.2006, p. 1015-1023.

Research output: Contribution to journalArticle

Lizanecz, Erzsébet ; Bagi, Zsolt ; Pásztor, Eniko T. ; Papp, Zoltán ; Édes, István ; Kedei, Noémi ; Blumberg, Peter M. ; Tóth, Attila. / Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1. In: Molecular Pharmacology. 2006 ; Vol. 69, No. 3. pp. 1015-1023.
@article{708bbb6239f0474794727f95e24bdf79,
title = "Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1",
abstract = "It has been proposed that activation of vanilloid receptor-1 (TRPV1) affects the vasotone of resistance arteries. One of the endogenous activators of TRPV1 is anandamide. The effects of anandamide on TRPV1 responsiveness were tested on isolated, pressurized (80 mm Hg) skeletal muscle (m. gracilis) arterioles (179 ± 33 μm in diameter). We found that the TRPV1 agonist capsaicin (1 μM) elicited a substantial constriction in isolated arterioles (51 ± 12{\%}). In contrast, anandamide (0-100 μM) did not affect arteriolar diameter significantly (3 ± 5{\%}). Isolated vessels were also preincubated with anandamide (30 μM for 20 min). This anandamide pretreatment completely blocked capsaicin-induced arteriolar constriction (response decreased to 1 ± 0.6{\%}), and this inhibition was reversed by a protein phosphatase-2B inhibitor (cyclosporin-A; 100 nM, 5 min) treatment (constriction, 31 ± 1{\%}). An exogenous TRPV1-expressing cell line [Chinese hamster ovary (CHO)-TRPV1] was used to specifically evaluate TRPV1-mediated effects of anandamide. The efficacy of anandamide in this system, as determined by 45Ca2+ uptake, was 65 ± 8{\%} of that of capsaicin. Upon treatment of the cells with cyclosporin-A or the protein kinase C activator phorbol 12-myristate 13-acetate (PMA), anandamide was transformed to a full agonist. Anandamide treatment caused an acute desensitization in these cells as measured by intracellular Ca2+ imaging. Application of cyclosporin-A or PMA reversed this desensitization. Our data suggest that anandamide may cause a complete (albeit phosphorylation-dependent) desensitization of TRPV1 in skeletal muscle arterioles and in CHO-TRPV1 cells, which apparently transforms the ligand-gated TRPV1 into a phosphorylation-gated channel. This property of anandamide may provide a new therapeutic strategy to manipulate TRPV1 activity.",
author = "Erzs{\'e}bet Lizanecz and Zsolt Bagi and P{\'a}sztor, {Eniko T.} and Zolt{\'a}n Papp and Istv{\'a}n {\'E}des and No{\'e}mi Kedei and Blumberg, {Peter M.} and Attila T{\'o}th",
year = "2006",
month = "3",
day = "1",
doi = "10.1124/mol.105.015644",
language = "English (US)",
volume = "69",
pages = "1015--1023",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1

AU - Lizanecz, Erzsébet

AU - Bagi, Zsolt

AU - Pásztor, Eniko T.

AU - Papp, Zoltán

AU - Édes, István

AU - Kedei, Noémi

AU - Blumberg, Peter M.

AU - Tóth, Attila

PY - 2006/3/1

Y1 - 2006/3/1

N2 - It has been proposed that activation of vanilloid receptor-1 (TRPV1) affects the vasotone of resistance arteries. One of the endogenous activators of TRPV1 is anandamide. The effects of anandamide on TRPV1 responsiveness were tested on isolated, pressurized (80 mm Hg) skeletal muscle (m. gracilis) arterioles (179 ± 33 μm in diameter). We found that the TRPV1 agonist capsaicin (1 μM) elicited a substantial constriction in isolated arterioles (51 ± 12%). In contrast, anandamide (0-100 μM) did not affect arteriolar diameter significantly (3 ± 5%). Isolated vessels were also preincubated with anandamide (30 μM for 20 min). This anandamide pretreatment completely blocked capsaicin-induced arteriolar constriction (response decreased to 1 ± 0.6%), and this inhibition was reversed by a protein phosphatase-2B inhibitor (cyclosporin-A; 100 nM, 5 min) treatment (constriction, 31 ± 1%). An exogenous TRPV1-expressing cell line [Chinese hamster ovary (CHO)-TRPV1] was used to specifically evaluate TRPV1-mediated effects of anandamide. The efficacy of anandamide in this system, as determined by 45Ca2+ uptake, was 65 ± 8% of that of capsaicin. Upon treatment of the cells with cyclosporin-A or the protein kinase C activator phorbol 12-myristate 13-acetate (PMA), anandamide was transformed to a full agonist. Anandamide treatment caused an acute desensitization in these cells as measured by intracellular Ca2+ imaging. Application of cyclosporin-A or PMA reversed this desensitization. Our data suggest that anandamide may cause a complete (albeit phosphorylation-dependent) desensitization of TRPV1 in skeletal muscle arterioles and in CHO-TRPV1 cells, which apparently transforms the ligand-gated TRPV1 into a phosphorylation-gated channel. This property of anandamide may provide a new therapeutic strategy to manipulate TRPV1 activity.

AB - It has been proposed that activation of vanilloid receptor-1 (TRPV1) affects the vasotone of resistance arteries. One of the endogenous activators of TRPV1 is anandamide. The effects of anandamide on TRPV1 responsiveness were tested on isolated, pressurized (80 mm Hg) skeletal muscle (m. gracilis) arterioles (179 ± 33 μm in diameter). We found that the TRPV1 agonist capsaicin (1 μM) elicited a substantial constriction in isolated arterioles (51 ± 12%). In contrast, anandamide (0-100 μM) did not affect arteriolar diameter significantly (3 ± 5%). Isolated vessels were also preincubated with anandamide (30 μM for 20 min). This anandamide pretreatment completely blocked capsaicin-induced arteriolar constriction (response decreased to 1 ± 0.6%), and this inhibition was reversed by a protein phosphatase-2B inhibitor (cyclosporin-A; 100 nM, 5 min) treatment (constriction, 31 ± 1%). An exogenous TRPV1-expressing cell line [Chinese hamster ovary (CHO)-TRPV1] was used to specifically evaluate TRPV1-mediated effects of anandamide. The efficacy of anandamide in this system, as determined by 45Ca2+ uptake, was 65 ± 8% of that of capsaicin. Upon treatment of the cells with cyclosporin-A or the protein kinase C activator phorbol 12-myristate 13-acetate (PMA), anandamide was transformed to a full agonist. Anandamide treatment caused an acute desensitization in these cells as measured by intracellular Ca2+ imaging. Application of cyclosporin-A or PMA reversed this desensitization. Our data suggest that anandamide may cause a complete (albeit phosphorylation-dependent) desensitization of TRPV1 in skeletal muscle arterioles and in CHO-TRPV1 cells, which apparently transforms the ligand-gated TRPV1 into a phosphorylation-gated channel. This property of anandamide may provide a new therapeutic strategy to manipulate TRPV1 activity.

UR - http://www.scopus.com/inward/record.url?scp=33644844634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644844634&partnerID=8YFLogxK

U2 - 10.1124/mol.105.015644

DO - 10.1124/mol.105.015644

M3 - Article

C2 - 16338989

AN - SCOPUS:33644844634

VL - 69

SP - 1015

EP - 1023

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -